Minimally invasive eye surgery could ease a rare form of glaucoma

NCT ID NCT07713056

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This study looks at pigmentary glaucoma, a rare type of glaucoma caused by pigment flakes blocking fluid drainage in the eye. Researchers are testing a minimally invasive surgery called ab-interno 120° trabeculotomy, which makes a small cut in the eye's drainage tissue to help fluid flow out and lower pressure. The study follows 11 people for 6 months after surgery to see if eye pressure drops and if they need fewer glaucoma medications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a minimally invasive glaucoma surgery called ab-interno 120° trabeculotomy
What this could lead to
If successful, this surgery could offer a safer, effective way to lower eye pressure and reduce medication use in people with pigmentary glaucoma.
What could go wrong
This is a small, early study with only 11 participants and no comparison group, so results may not apply to all patients. The surgery may not lower pressure enough or could have complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PIGMENTARY GLAUCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Zhongnan Hospital of Wuhan University

    RECRUITING

    Wuhan, Hubei, 430071, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.